Segall Bryant & Hamill LLC Boosts Holdings in Qiagen (NYSE:QGEN)

Segall Bryant & Hamill LLC grew its holdings in Qiagen (NYSE:QGEN) by 1.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,842 shares of the company’s stock after purchasing an additional 2,310 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Qiagen were worth $6,418,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Janney Montgomery Scott LLC increased its position in Qiagen by 18.3% during the first quarter. Janney Montgomery Scott LLC now owns 7,433 shares of the company’s stock worth $320,000 after buying an additional 1,151 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Qiagen by 10.3% in the 1st quarter. Acadian Asset Management LLC now owns 45,471 shares of the company’s stock valued at $1,944,000 after acquiring an additional 4,253 shares during the last quarter. PEAK6 Investments LLC increased its stake in Qiagen by 270.0% in the first quarter. PEAK6 Investments LLC now owns 7,925 shares of the company’s stock valued at $341,000 after purchasing an additional 12,587 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Qiagen by 13.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 91,763 shares of the company’s stock valued at $3,945,000 after acquiring an additional 10,683 shares during the last quarter. Finally, Earnest Partners LLC grew its stake in shares of Qiagen by 85.1% during the 1st quarter. Earnest Partners LLC now owns 3,427,605 shares of the company’s stock valued at $147,353,000 after buying an additional 1,576,259 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on QGEN. Robert W. Baird lifted their price objective on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $50.88.

Qiagen Price Performance

QGEN opened at $42.33 on Friday. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The firm has a market cap of $9.66 billion, a price-to-earnings ratio of 108.54, a PEG ratio of 3.16 and a beta of 0.41. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The company has a fifty day simple moving average of $43.57 and a 200 day simple moving average of $43.73.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.